(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 February 2015 (19.02.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/023710 A1

(51) International Patent Classification:
A61K 31/58 (2006.01) *C07J 43/00* (2006.01)

(21) International Application Number:
PCT/US2014/050793

(22) International Filing Date:
12 August 2014 (12.08.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/865,038	12 August 2013 (12.08.2013)	US
61/990,570	8 May 2014 (08.05.2014)	US
62/002,110	22 May 2014 (22.05.2014)	US

(71) Applicant: **TOKAI PHARMACEUTICALS, INC.** [US/US]; One Broadway, 14th Floor, Cambridge, MA 02142 (US).

(72) Inventors; and
(71) Applicants : **NJAR, Vincent** [US/US]; 7908 Springridge Road, Glen Burnie, MD 21060 (US). **ZOUBEIDI, Amina** [CA/CA]; 6331 Imperial Avenue, Vancouver, BC V7W2J5 (CA). **FERRANTE, Karen** [US/US]; One Broadway, 14th Floor, Cambridge, MA 02142 (US). **COREY, Eva** [US/US]; 1959 N.e. Pacific St., Seattle, WA 98195 (US).

(72) Inventor: **JACOBY, Douglas**; One Broadway, 14th Floor, Cambridge, MA 02142 (US).


(74) Agents: **ORBAI, Lucian** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: BIOMARKERS FOR TREATMENT OF NEOPLASTIC DISORDERS USING ANDROGEN-TARGETED THERAPIES



(II)

(57) Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.

WO 2015/023710 A1

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*